scholarly journals Association of genetic variation of the six gene prognostic model for castration-resistant prostate cancer with survival

The Prostate ◽  
2018 ◽  
Vol 79 (1) ◽  
pp. 73-80 ◽  
Author(s):  
Wanling Xie ◽  
Konrad H. Stopsack ◽  
Sarah J. Drouin ◽  
Henry Fu ◽  
Mark M. Pomerantz ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Prognostic Model ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients

2020 ◽  
Vol 38 (6) ◽  
pp. 600.e9-600.e15
Author(s):  
Judith Stangl-Kremser ◽  
Andrea Mari ◽  
Rodrigo Suarez-Ibarrola ◽  
David D'Andrea ◽  
Stephan M. Korn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Prognostic Model ◽  
Castration Resistant Prostate Cancer ◽  
Time Prediction ◽  
Castration Resistant

scholarly journals Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

2014 ◽  
Vol 32 (7) ◽  
pp. 671-677 ◽  
Author(s):  
Susan Halabi ◽  
Chen-Yen Lin ◽  
W. Kevin Kelly ◽  
Karim S. Fizazi ◽  
Judd W. Moul ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Model ◽  
Risk Groups ◽  
Phase Iii ◽  
Castration Resistant Prostate Cancer ◽  
First Line ◽  
Phase Iii Trial ◽  
Castration Resistant ◽  
Validation Set ◽  
Line Chemotherapy

Purpose Prognostic models for overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC) are dated and do not reflect significant advances in treatment options available for these patients. This work developed and validated an updated prognostic model to predict OS in patients receiving first-line chemotherapy. Methods Data from a phase III trial of 1,050 patients with mCRPC were used (Cancer and Leukemia Group B CALGB-90401 [Alliance]). The data were randomly split into training and testing sets. A separate phase III trial served as an independent validation set. Adaptive least absolute shrinkage and selection operator selected eight factors prognostic for OS. A predictive score was computed from the regression coefficients and used to classify patients into low- and high-risk groups. The model was assessed for its predictive accuracy using the time-dependent area under the curve (tAUC). Results The model included Eastern Cooperative Oncology Group performance status, disease site, lactate dehydrogenase, opioid analgesic use, albumin, hemoglobin, prostate-specific antigen, and alkaline phosphatase. Median OS values in the high- and low-risk groups, respectively, in the testing set were 17 and 30 months (hazard ratio [HR], 2.2; P < .001); in the validation set they were 14 and 26 months (HR, 2.9; P < .001). The tAUCs were 0.73 (95% CI, 0.70 to 0.73) and 0.76 (95% CI, 0.72 to 0.76) in the testing and validation sets, respectively. Conclusion An updated prognostic model for OS in patients with mCRPC receiving first-line chemotherapy was developed and validated on an external set. This model can be used to predict OS, as well as to better select patients to participate in trials on the basis of their prognosis.

Germline genetic variation inJAK2as a prognostic marker in castration-resistant prostate cancer

2016 ◽  
Vol 119 (3) ◽  
pp. 489-495 ◽  
Author(s):  
Ben Y. Zhang ◽  
Shaun M. Riska ◽  
Douglas W. Mahoney ◽  
Brian A. Costello ◽  
Rhea Kohli ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Genetic Variation ◽  
Prognostic Marker ◽  
Castration Resistant Prostate Cancer ◽  
Castration Resistant

scholarly journals A robust blood gene expression-based prognostic model for castration-resistant prostate cancer

BMC Medicine ◽  
2015 ◽  
Vol 13 (1) ◽  
Author(s):  
Li Wang ◽  
Yixuan Gong ◽  
Uma Chippada-Venkata ◽  
Matthias Michael Heck ◽  
Margitta Retz ◽  
...  
Keyword(s):  
Gene Expression ◽  
Prostate Cancer ◽  
Prognostic Model ◽  
Castration Resistant Prostate Cancer ◽  
Blood Gene Expression ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document